JP2022500042A5 - - Google Patents
Info
- Publication number
- JP2022500042A5 JP2022500042A5 JP2021513989A JP2021513989A JP2022500042A5 JP 2022500042 A5 JP2022500042 A5 JP 2022500042A5 JP 2021513989 A JP2021513989 A JP 2021513989A JP 2021513989 A JP2021513989 A JP 2021513989A JP 2022500042 A5 JP2022500042 A5 JP 2022500042A5
- Authority
- JP
- Japan
- Prior art keywords
- lmdv
- antigen
- heavy chain
- substitution
- binding moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731356P | 2018-09-14 | 2018-09-14 | |
| US62/731,356 | 2018-09-14 | ||
| PCT/US2019/050823 WO2020056145A1 (en) | 2018-09-14 | 2019-09-12 | Anti-hiv antibody 10-1074 variants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022500042A JP2022500042A (ja) | 2022-01-04 |
| JP2022500042A5 true JP2022500042A5 (https=) | 2022-09-16 |
Family
ID=69778483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513989A Pending JP2022500042A (ja) | 2018-09-14 | 2019-09-12 | 抗ｈｉｖ抗体１０−１０７４バリアント |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12441782B2 (https=) |
| EP (1) | EP3849612A4 (https=) |
| JP (1) | JP2022500042A (https=) |
| KR (1) | KR102938690B1 (https=) |
| CN (2) | CN121021680A (https=) |
| AU (1) | AU2019338454A1 (https=) |
| CA (1) | CA3112486A1 (https=) |
| WO (1) | WO2020056145A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202231277A (zh) | 2019-05-21 | 2022-08-16 | 美商基利科學股份有限公司 | 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法 |
| JP7518286B2 (ja) | 2020-08-25 | 2024-07-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖを標的とする多重特異性抗原結合分子及び使用方法 |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| PL4244396T3 (pl) | 2020-11-11 | 2025-12-22 | Gilead Sciences, Inc. | Sposoby identyfikacji pacjentów z hiv wrażliwych na terapię przeciwciałami skierowanymi na miejsce wiązania cd4 gp120 |
| US20250152710A1 (en) * | 2022-02-08 | 2025-05-15 | James L. Riley | Modified primary immune cells for induction or enhancement of immunotherapy |
| AU2023330037A1 (en) | 2022-08-26 | 2025-03-06 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6593A (en) | 1849-07-17 | Cutting | ||
| US81A (en) | 1836-11-15 | Erawijjg | ||
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| GB9206318D0 (en) | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US6492160B1 (en) | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Technology Ltd. | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| US5962255A (en) | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ES2162863T3 (es) | 1993-04-29 | 2002-01-16 | Unilever Nv | Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae. |
| AU4289496A (en) | 1994-12-02 | 1996-06-19 | Chiron Corporation | Method of promoting an immune response with a bispecific antibody |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| PT3556396T (pt) * | 2010-08-31 | 2022-07-04 | Scripps Research Inst | Anticorpos neutralizantes do vírus da imunodeficiência humana (vih) |
| CN103797029B (zh) * | 2011-05-17 | 2016-08-17 | 洛克菲勒大学 | 人类免疫缺陷病毒中和抗体及其使用方法 |
| US9879068B2 (en) * | 2012-06-21 | 2018-01-30 | California Institute Of Technology | Antibodies targeting HIV escape mutants |
| CN118955699A (zh) * | 2012-10-18 | 2024-11-15 | 洛克菲勒大学 | 广泛中和性抗hiv抗体 |
| WO2016014484A1 (en) * | 2014-07-21 | 2016-01-28 | The Rockefeller University | Combination of broadly neutralizing hiv antibodies and viral inducers |
| BR112019013468A8 (pt) | 2016-12-27 | 2022-11-22 | Univ Rockefeller | Anticorpos anti-hiv-1 amplamente neutralizante e métodos de uso dos mesmos |
| WO2020086782A1 (en) | 2018-10-24 | 2020-04-30 | The Wistar Institute Of Anatomy And Biology | Dna antibody constructs for use against hiv |
-
2019
- 2019-09-12 AU AU2019338454A patent/AU2019338454A1/en active Pending
- 2019-09-12 KR KR1020217011145A patent/KR102938690B1/ko active Active
- 2019-09-12 CN CN202511190725.6A patent/CN121021680A/zh active Pending
- 2019-09-12 US US17/275,310 patent/US12441782B2/en active Active
- 2019-09-12 CA CA3112486A patent/CA3112486A1/en active Pending
- 2019-09-12 CN CN201980074145.7A patent/CN113271974B/zh active Active
- 2019-09-12 WO PCT/US2019/050823 patent/WO2020056145A1/en not_active Ceased
- 2019-09-12 EP EP19859927.6A patent/EP3849612A4/en active Pending
- 2019-09-12 JP JP2021513989A patent/JP2022500042A/ja active Pending
-
2025
- 2025-08-13 US US19/298,749 patent/US20260049122A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022500042A5 (https=) | ||
| US20150132255A1 (en) | Hiv vaccine | |
| TW202104210A (zh) | Hiv蛋白酶抑制劑 | |
| MX2010006148A (es) | Anti-cuerpos contra el virus de la influenza y metodos de uso de los mismos. | |
| US20180140694A1 (en) | Dosage regimen for hiv vaccine | |
| JP2022515770A5 (https=) | ||
| JP2022528020A5 (https=) | ||
| US20170165321A1 (en) | Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids) | |
| JP2017529326A5 (https=) | ||
| Ahmed et al. | mRNA-based HIV-1 vaccines | |
| EP1096953B1 (fr) | Utilisation de proteines immunogenes immunosuppressives et/ou angiogeniques rendues inactives, procede de preparation et applications pharmaceutiques ou vaccinales | |
| ES2360334T3 (es) | Composiciones farmacéuticas de anticuerpos para enfermedades causadas por virus. | |
| Stein et al. | Immune-based therapeutics: scientific rationale and the promising approaches to the treatment of the human immunodeficiency virus-infected individual | |
| Harfouch et al. | Therapeutic approaches for COVID 19: Challenges and successes | |
| WO2015086738A2 (en) | Hiv vaccine | |
| US10449245B2 (en) | Method for reducing HIV-1 reservoir size using multivalent immunogen and reservoir purging agent | |
| EA013008B1 (ru) | Композиции аполактоферрина и способы их применения в лечении вирусного гепатита с | |
| JP2022513438A5 (https=) | ||
| DE602007010127D1 (en) | Hiv-impfstoff | |
| JP2014512353A (ja) | 抗ウイルス組成物 | |
| US7015016B2 (en) | Use of inactivated immunosuppressive or angiogenic immunogenic proteins for producing secretory IgA's | |
| AU2015208033B2 (en) | Method for the vaccination against HIV | |
| JP2004002455A (ja) | レトロウイルス感染の阻害 | |
| JP2014510126A5 (ja) | Ｉｆｎアルファ関連疾病の処置方法 | |
| ES2150107T5 (es) | Inmunogenos no toxicos que proceden de una proteina de regulacion retroviral, anticuerpos dirigidos contra estos inmunogenos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. |